Sorafenib (Nexavar, a novel bi-aryl urea BAY 43–9006), is an oral multikinase inhibitor that blocks tumor cell proliferation and carcinogenesis by targeting the Raf/MEK/ERK signaling pathway and exerts an antiangiogenic effect by targeting several receptor tyrosine kinases including VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor (PDGFR)-beta [37, 38]. This evidence concerns the gene FLT4 and neoplasm.